ATE542535T1 - Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten - Google Patents

Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Info

Publication number
ATE542535T1
ATE542535T1 AT06724715T AT06724715T ATE542535T1 AT E542535 T1 ATE542535 T1 AT E542535T1 AT 06724715 T AT06724715 T AT 06724715T AT 06724715 T AT06724715 T AT 06724715T AT E542535 T1 ATE542535 T1 AT E542535T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
azapaullone
autoimmune diseases
pancreatic autoimmune
Prior art date
Application number
AT06724715T
Other languages
English (en)
Inventor
Rainer Mussmann
Conrad Kunick
Hendrik Stukenbrock
Marcus Geese
Simone Kegel
Ulrike Burk
Original Assignee
Develogen Ag
Tech Uni Carolo Wilhelmina Zu Braunschweig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Tech Uni Carolo Wilhelmina Zu Braunschweig filed Critical Develogen Ag
Application granted granted Critical
Publication of ATE542535T1 publication Critical patent/ATE542535T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06724715T 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten ATE542535T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05009846 2005-05-04
EP05015986 2005-07-22
EP05023168 2005-10-24
EP06001327 2006-01-23
PCT/EP2006/004186 WO2006117221A1 (en) 2005-05-04 2006-05-04 Use of azapaullones for preventing and treating pancreatic autoimmune disorders

Publications (1)

Publication Number Publication Date
ATE542535T1 true ATE542535T1 (de) 2012-02-15

Family

ID=36625260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724715T ATE542535T1 (de) 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Country Status (4)

Country Link
US (1) US7968535B2 (de)
EP (1) EP1879591B8 (de)
AT (1) ATE542535T1 (de)
WO (1) WO2006117221A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Mch 길항물질로서 (1-아지논)-치환된 피리도인돌
AU2010239396B2 (en) 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ, インコーポレイテッド アジノン置換アゼピノ[b]インドールおよびピリド−ピロロ−アゼピンmch−1拮抗薬、ならびにその作製方法および使用
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US9161953B2 (en) 2010-12-22 2015-10-20 Amylin Pharmaceuticals, Llc GLP-1 receptor agonists for islet cell transplantation
EP3920885A1 (de) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を治療するための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
WO2002086107A2 (en) 2001-04-19 2002-10-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung A method for differentiating stem cells into insulin-producing cells
HUP0401403A3 (en) * 2001-08-03 2005-11-28 Novo Nordisk As 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
CA2477117A1 (en) 2002-02-22 2003-08-28 Teijin Limited Pyrrolopyrimidine derivative
WO2003076442A1 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
US20080187492A1 (en) * 2004-04-16 2008-08-07 Mcbride Sean M J Drosophila Models For Diseases Affecting Learning and Memory

Also Published As

Publication number Publication date
EP1879591A1 (de) 2008-01-23
WO2006117221A1 (en) 2006-11-09
EP1879591B8 (de) 2012-04-04
US7968535B2 (en) 2011-06-28
US20080287423A1 (en) 2008-11-20
EP1879591B1 (de) 2012-01-25

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
TW200716140A (en) Treatment of inflammatory conditions
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE521608T1 (de) Glucokinaseaktivatoren
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
TWI319708B (en) Methods and compositions for altering cell fuction
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
TW200716132A (en) Novel chemical compounds
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.